EmbryoCheck is a next-generation sequencing (NGS) test performed on embryos created through in-vitro fertilization (IVF). Also known as Pre-Implantation Genetic Testing for Aneuploidy (PGT-A) or Pre-Implantation Genetic Screening (PGS), this test evaluates the chromosomal status of embryos before implantation.

Why EmbryoCheck?

Embryos with an abnormal number of chromosomes (aneuploid embryos) often fail to implant, result in miscarriage, or may lead to the birth of a child with a genetic condition. By screening embryos for chromosomal abnormalities, EmbryoCheck helps improve IVF success rates and supports the selection of embryos with the highest potential for a healthy pregnancy.

How EmbryoCheck works?

• Analyzes all 23 pairs of chromosomes
• Detects chromosomal imbalances such as trisomy (extra chromosome) or monosomy (missing chromosome)
• Provides crucial insights into embryo health before transfer

Who should consider EmbryoCheck?

PGT-A may be recommended for:

• Women of advanced maternal age (≥35 years old)

• Couples with repeated implantation failure

• Couples with recurrent miscarriage

• Individuals or couples with a history of chromosomal abnormalities in a child

Key Benefits

• Increases the chance of successful implantation

• Reduces the risk of miscarriage

• Improves IVF outcomes by selecting the healthiest embryos

• Provides reassurance and confidence in family planning